Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... vaccine that covers all cancer-causing types, reduces or eliminates the need for Pap testing and costs less than commercially available vaccines. Principal investigators are ... human papillomavirus (HPV) vaccines for the prevention of cervical cancer and test more therapeutic agents that have shown promise in preventing, slowing or effectively ...
2009 NOV 9 ... and screened 49,222 patients and 124 practices were assigned to use the conventional PAP test and screened 40,562 patients. Patients were screened for cervical intraepithelial ...
2009 NOV 16 ... with the CyPath® assay in the Biomoda lab. Results are compared to CT scans and Pap stains read by independent radiologists and cytopathologists, respectively, to confirm ... Biomoda product lines and medical diagnostics. The company's first product, an in-vitro test for the detection of early-stage lung cancer, is currently in Phase II clinical trials. ...
2009 NOV 23 ... with the CyPath® assay in the Biomoda lab. Results are compared to CT scans and Pap stains read by independent radiologists and cytopathologists, respectively, to confirm ... soon will change for the better." Biomoda's first product, an in-vitro test for the detection of early-stage lung cancer, is currently in Phase II clinical trials. ...
2009 NOV 9 ... them understand their potential risk for breast cancer. Based on the same science as the PAP test for cervical cell changes, HALO=AE is the only FDA-cleared risk assessment tool for ...
2009 NOV 16 ... help women and their doctors decide what to do about the mildly abnormal and very common Pap test results known as ASCUS and LSIL. About three million women in the United States are ...
2009 NOV 29 ... this enrichment step may preserve the positive predictive value of the HPV-followed-by Pap approach.Keywords: Cancer, Colposcopy, Cytology, DNA, Oncology, Surgery, ... MPH, DrPH, said that "this finding underscores the importance of cytology as a triage test in preserving the specificity of the HPV DNA screening approach."He also ...
2009 NOV 9 ... of delivering the service in a clinical setting. Those seven included cervical cancer (Pap test), Chlamydia (girls), depression, tobacco, and for persons at increased risk of ...
2009 NOV 1 ... under normoxic and hypoxic conditions. Patients with PH (mean pulmonary artery pressure [PAP], >= 25 mm Hg) had lower Pao(2) and higher plasma IL-6 values than those without PH; ... values than those without PH; there were no differences in terms of pulmonary function test results or CT scan emphysema scores. Plasma IL-6 correlated with mean PAP (r = 0.39; ...
2009 NOV 9 ... 109 participants was 31 years, the median CD4 count was 125/mm(3), 66.3% had an abnormal Pap smear, the HR-HPV prevalence was 78.9% (Digene), the median HPV viral load was 181.1 RLU ... were taken for cytological analysis and HPV testing. The Digene Hybrid Capture 2 (HC2) test was used to detect HR-HPV. Relative light units (RLU) were used as a measure of HPV ...
2009 NOV 2 ... or recurrent disease was identified in 17 patients (17.9%) during a 24-month period. A Pap smear significantly predicted disease recurrence at the first follow-up visit only. At ... (LEEP) for high-grade CIN were followed-up with HR-HPV DNA testing (Hybrid Capture II test, Digene Diagnostics, Gaithersburg, MD, USA) and cytology at 3, 6, 12, 18 and 24 months ...
2009 NOV 2 ... the New Independent States of the former Soviet Union (NIS) cohort study. Conventional Pap smears were classified in NIS laboratories and rescreened in a reference center (RC) ... to Bethesda System (TBS) and demonstrate effect of verification bias correction on test performance in the New Independent States of the former Soviet Union (NIS) cohort study. ...
2009 NOV 23 ... tended to be lower in older women, women with more partners, and women with abnormal Pap test results," wrote S.K. Kjaer and colleagues, University of Copenhagen. The ...
2009 NOV 1 ... women to be 27% less likely to exercise (CI, 0.67-0.79), 62% less likely to receive a Pap test (CI, 0.31-0.46), 19% less likely to have HIV testing (CI, 0.75-0.87), and 44% less ...
2009 NOV 17 ... Other screenings eligible for the wellness benefit include colonoscopy, mammography, Pap smear, PSA test for prostate cancer, serum cholesterol test, among others. ...
2009 NOV 1 ... positive results for the HPV High Risk DNA test but negative cervical cytology screen/Pap smears. Cervical cytology screening, either conventional Pap smears or ...
2009 NOV 16 ... URL Pharma is establishing a Fibricor patient assistance program (PAP) for patients who are qualified. The program is expected to launch by the fourth quarter ... and coronary heart disease. Your doctor may periodically perform a simple blood test to monitor the health of your liver or kidneys while taking FIBRICOR. You should tell ...
2009 NOV 23 ... of products for the North American market." At present, about 55 million Pap smears and 10 million HPV tests are performed annually in the US. The U.S. market for ... which was developed by Merck & Co. (NYSE: MRK). The TrovaGene HPV DNA test involves isolation of DNA from urine and specific PCR amplification of the HPV E1 region ...
